PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-22.03%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-22.30%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-22.29%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.29%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Negative OCF growth while Healthcare median is -11.35%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-72.45%
Negative FCF growth while Healthcare median is -8.86%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
42.89%
OCF/share CAGR of 42.89% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
64.68%
3Y OCF/share growth of 64.68% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-7255.64%
Negative 10Y net income/share CAGR vs. Healthcare median of 9.51%. Seth Klarman might see a fundamental problem if peers maintain growth.
-121.67%
Negative 5Y CAGR while Healthcare median is 1.60%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
22.78%
3Y net income/share CAGR > 1.5x Healthcare median of 0.20%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
5223.15%
Equity/share CAGR of 5223.15% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
855.06%
5Y equity/share CAGR > 1.5x Healthcare median of 20.07%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-50.27%
Negative 3Y equity/share growth while Healthcare median is 1.53%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
59.08%
BV/share growth of 59.08% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth of 15.66% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
40.35%
SG&A growth of 40.35% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.